rs11061946 — ADIPOR2

Intronic variant in the adiponectin receptor 2 gene; rare homozygotes showed a markedly elevated risk of progression from impaired glucose tolerance to type 2 diabetes in a single Finnish cohort study, though evidence remains emerging and unreplicated.

See your personal result for ADIPOR2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ADIPOR2 rs11061946 — A Rare Signal in the Adiponectin Receptor

Adiponectin is one of the few adipokines that works against metabolic disease: it rises with fat loss, improves insulin sensitivity, suppresses hepatic glucose production, and triggers fatty acid oxidation11 fatty acid oxidation
the breakdown of fat for fuel, primarily in liver and muscle through the PPARα pathway. The receptor through which adiponectin acts in the liver is ADIPOR2 (Adiponectin Receptor 2, gene symbol ADIPOR2, chromosome 12p13.31). Unlike its partner ADIPOR1 — the predominant muscle receptor — ADIPOR2 is most abundantly expressed in hepatic tissue, where it couples adiponectin signaling to the PPARα pathway22 PPARα pathway
Peroxisome proliferator-activated receptor alpha, a nuclear receptor that upregulates enzymes for fatty acid β-oxidation and downregulates hepatic gluconeogenesis and pro-inflammatory gene programs. Disrupting AdipoR2 in mice impairs hepatic fatty acid oxidation, worsens diet-induced insulin resistance, and elevates fasting glucose, establishing a clear causal role for the receptor in metabolic homeostasis.

rs11061946 is an intronic variant located in intron 1 of ADIPOR2. It does not change any amino acid and has not been shown to alter splicing or gene expression in available functional studies. It may be a marker in linkage disequilibrium with a nearby causal variant, or it may itself influence chromatin accessibility or transcription factor binding in a context not yet captured by available expression datasets.

The Mechanism

The variant sits in intron 1 of ADIPOR233 intron 1 of ADIPOR2
The first intron, between the first and second coding exons; intronic variants can affect mRNA splicing, act as regulatory elements, or simply be neutral markers for nearby functional variants. No allele-specific differences in ADIPOR2 mRNA expression were detected in peripheral blood mononuclear cells or subcutaneous adipose tissue in the Genobin sub-study (56 subjects). The authors of the Finnish DPS paper explicitly noted that rs11061946 and its LD partner rs11061973 "are intronic SNPs, have no known functional significance, and may therefore be merely markers in LD with a true causal variant." The working hypothesis is that reduced or altered ADIPOR2 activity in rare TT homozygotes impairs hepatic adiponectin signaling, reducing PPARα-driven fatty acid oxidation and leaving the liver less able to suppress gluconeogenesis — a mechanism consistent with T2D progression, but not yet mechanistically demonstrated for this variant specifically.

rs11061946 is in strong linkage disequilibrium (r² = 0.674) with rs11061973, another intronic ADIPOR2 variant. The two SNPs co-segregate tightly: all five TT homozygotes at rs11061946 in the Finnish DPS were also AA homozygotes at rs11061973, meaning the signal may reflect a haplotype effect across this region of intron 1 rather than either SNP individually.

The Evidence

The primary evidence comes from the Finnish Diabetes Prevention Study (DPS)44 Finnish Diabetes Prevention Study (DPS)
A randomized controlled trial of 484 overweight adults with impaired glucose tolerance; intervention arm received intensive diet and exercise counseling, control arm received general information; median follow-up 7 years. Eight ADIPOR2 SNPs were genotyped. In a Cox proportional-hazards model adjusted for age, sex, study arm, baseline waist circumference, and fasting glucose:

  • TT genotype (n = 5): HR = 5.54 (95% CI 2.01–15.23), p = 0.001
  • CT genotype (n = 49): HR = 0.71 (95% CI 0.41–1.21), p = 0.206
  • CC genotype (n = 428): reference

The TT finding is striking numerically, but critical limitations apply. Only five individuals carried the TT genotype across the entire study, making the confidence interval very wide. The dominant inheritance model (CT + TT vs. CC) showed no significant association, indicating the risk is concentrated in the rare homozygote and does not manifest in heterozygotes. The study has not been replicated in an independent cohort, and a q-value (false discovery rate) correction of 0.369 for the TT result indicates that at this sample size, the finding does not survive multiple testing correction. rs11061946 also deviated from Hardy-Weinberg equilibrium in this Finnish sample — the authors retained it in analysis but flagged this as potentially reflecting small-sample chance deviation.

No association was found with cardiovascular disease outcomes in the same cohort. Broader ADIPOR2 SNP studies in UK populations (PMID 17216283) and Caucasian cohorts (PMID 16505255) did not report rs11061946 specifically, and none of 24 ADIPOR1/R2 polymorphisms were associated with T2D or insulin phenotypes in the larger UK replication sets.

Practical Actions

For the ~1% of people who are TT homozygotes, the Finnish DPS data suggest a substantially elevated hazard of progressing from impaired glucose tolerance to type 2 diabetes, though this signal has not been independently replicated. For CT heterozygotes (~14%), no statistically significant risk above baseline was observed.

Given that ADIPOR2 mediates adiponectin-driven hepatic fatty acid oxidation through PPARα, the metabolically meaningful intervention for anyone with impaired glucose tolerance — independent of genotype — is to support adiponectin activity. Adiponectin rises with weight loss, aerobic training, caloric restriction, and omega-3 fatty acid intake. For TT homozygotes specifically, the implication is that if receptor-level function is compromised, downstream metabolic support becomes more important: prioritizing dietary patterns that minimize hepatic fat accumulation (the chief driver of hepatic insulin resistance) and that avoid further suppression of adiponectin. Fasting glucose, 2-hour glucose tolerance, and HbA1c monitoring at the intervals used for clinical pre-diabetes management apply.

Interactions

rs11061946 is in moderate LD (r² = 0.674) with rs11061973, another intronic ADIPOR2 variant on the same haplotype block. The five TT individuals in the Finnish DPS were uniformly AA at rs11061973, suggesting a shared haplotype drives the risk rather than either variant independently. If both rs11061946 TT and rs11061973 AA are present together, the signal represents the same underlying haplotype — not an independent combinatorial risk.

The broader adiponectin pathway involves ADIPOQ (the adiponectin gene itself), ADIPOR1 (the complementary muscle-expressed receptor), and downstream transcription factors PPARA and PPARGC1A. Variants in these genes that reduce circulating adiponectin or impair receptor coupling could compound the effect of reduced ADIPOR2 activity, though no published compound analysis covers this specific combination.

Supervisor interaction proposal: rs11061946 TT + rs11061937 (the companion ADIPOR2 intronic variant) — if both variants tag a disrupted ADIPOR2 haplotype, combined homozygosity may indicate a more comprehensive ADIPOR2 functional deficit. Evidence is currently speculative (no compound study exists); propose as an interaction candidate for future investigation rather than a compound action today.

Nutrient Interactions

dietary fat altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Common Genotype Normal

Most common ADIPOR2 genotype — no elevated T2D progression risk at this locus

The CC genotype carries no known alteration to ADIPOR2 intronic sequence that would affect receptor expression, splicing, or function. In available expression studies (PBMC and adipose tissue), CC homozygotes and CT heterozygotes showed no significant difference in ADIPOR2 mRNA levels. The Finnish DPS Cox regression designated CC individuals (n=428, 88.4% of the cohort) as the reference group, with HR 1.0 for 7-year T2D incidence. No other large cohort study has reported rs11061946 in the context of T2D or metabolic traits, making this a clean negative: no detected signal in the majority genotype, and the elevated risk is confined to rare TT homozygotes only.

TT Rare Risk Genotype High Risk

Rare homozygous T genotype — markedly elevated T2D progression risk in single Finnish cohort study

The TT genotype co-segregated with TT/AA homozygosity at the LD partner rs11061973 (r²=0.674) in all five carriers in the Finnish DPS, indicating that the signal likely reflects a shared haplotype across this region of ADIPOR2 intron 1 rather than the single rs11061946 T allele independently. No functional mechanism has been established: allele-specific ADIPOR2 mRNA expression was not different in a sub-study of 56 individuals (though TT individuals were not among them, given their extreme rarity).

The biological plausibility is grounded in ADIPOR2's well-established hepatic role: when AdipoR2 signaling is impaired, PPARα-driven fatty acid oxidation decreases, hepatic triglyceride content rises, and insulin resistance worsens. This pathway is mechanistically linked to T2D progression. Whether the TT haplotype reduces ADIPOR2 expression, destabilizes the transcript, or is simply a proxy for a nearby causal coding or regulatory variant remains unknown.

The false discovery rate q-value of 0.369 (non-significant after correction) means this finding could be a false positive at this study size. The wide confidence interval (2.01–15.23) reflects the small n=5 TT group. Until replication in a larger cohort, the evidence level remains emerging.

The Finnish DPS was conducted in adults with impaired glucose tolerance (IGT), so the HR of 5.54 applies specifically to IGT progression, not general population T2D incidence from a normal baseline. TT individuals without IGT at baseline were not represented in this analysis.

CT Heterozygous Carrier Carrier

One T allele — no significant T2D risk elevation detected in available data

The CT genotype represents heterozygous carriage of the minor T allele. The Finnish DPS hazard ratio for CT vs. CC was 0.71 — slightly below 1.0, which is consistent with noise at this sample size and not indicative of any protective effect. The dominant inheritance model (CT + TT combined vs. CC) was tested and found non-significant, confirming that a single T allele does not meaningfully alter ADIPOR2-related T2D risk at this locus.

No allele-specific expression differences were found in CT vs. CC individuals in available functional datasets (PBMC or adipose tissue mRNA). The T allele in heterozygosity may be functionally inert, or any cis-regulatory effect may be insufficient to drive a phenotypic signal from a single copy. Given that only 5 individuals in the entire study were TT, the power to detect recessive effects was low — the null finding in CT is therefore not necessarily informative about the T allele's biological role; it may simply reflect a recessive pattern requiring two copies for penetrance.